The clinical benefit rate was higher with sacituzumab govitecan than with chemotherapy (34% vs.
22%).
The FDA has approved sacituzumab govitecan for patients with metastatic unresectable breast cancer, including patients with TNBC who have received at least two systemic therapies, including at least one for metastatic cancer.
It is also approved in patients with HER2-negative hormone receptor–positive breast cancer who have received hormone therapy and at least two systemic therapies for metastatic cancer.
Chemotherapy may be appropriate for patients with HER2-negative hormone receptor–positive breast cancer.